Todd M. Zimmerman - Concepedia

Author

Todd M. Zimmerman

Also Known As

Pawlish, Karen, T M Zimmerman, T Zimmerman, T. M. Zimmerman, T. Zimmerman, T.M. Zimmerman, TODD M. ZIMMERMAN, Todd M Zimmerman, Todd M. Zimmerman, Todd Zimmerman

141

Publications

5.6K

Citations

H-Index

Concepts

All Affiliations

University of Chicago Dana-Farber Cancer Institute Emory University Multiple Myeloma Research Foundation University of Chicago Medical Center

About

Todd M. Zimmerman is an author at University of Chicago specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	23	1.8K
2	Health Sciences	10	10	486
3	Cell Biology	3	3	84
4	Cellular Therapies	3	3	71
5	Blood Transplantation	1	1	32

Todd M. Zimmerman

Publications

5.3K

Citations

H-Index

Page 1

	Year	Citations
Initial genome sequencing and analysis of multiple myeloma Michael A. Chapman, Michael S. Lawrence, Jonathan J. Keats, Nature	2011	1.4K
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy Jens G. Lohr, Petar Stojanov, Scott L. Carter, Cancer Cell Hematological MalignancyDisease HeterogeneityWidespread Genetic HeterogeneityTumor HeterogeneityMedicine	2014	988
Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma Andrzej Jakubowiak, Don M. Benson, William Bensinger, Journal of Clinical Oncology	2012	202
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma Shaji Kumar, William Bensinger, Todd M. Zimmerman, Blood	2014	192
Allogeneic Stem-Cell Transplantation of Renal Cell Cancer After Nonmyeloablative Chemotherapy: Feasibility, Engraftment, and Clinical Results Brian I. Rini, Todd M. Zimmerman, Walter M. Stadler, Journal of Clinical Oncology	2002	174
Fludarabine, Melphalan, and Alemtuzumab Conditioning in Adults With Standard-Risk Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome Koen van Besien, Andrew Artz, Sonali M. Smith, Journal of Clinical Oncology	2005	140
Performance Status and Comorbidity Predict Transplant-Related Mortality After Allogeneic Hematopoietic Cell Transplantation Andrew Artz, Daniel A. Pollyea, Masha Kocherginsky, Biology of Blood and Marrow Transplantation	2006	132
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial Saad Z. Usmani, Antje Hoering, Sikander Ailawadhi, The Lancet Haematology Hematological MalignancyOncologyHematologyMyeloid NeoplasiaPrimary Analysis	2020	122
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial Andrzej Jakubowiak, Kent A. Griffith, Donna Reece, Blood	2011	89
Prognostic Factors for Survival With Gemcitabine Plus 5-fluorouracil Based Regimens for Metastatic Renal Cancer Walter M. Stadler, Dezheng Huo, Christopher George, The Journal of Urology	2003	88

Page 1